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Abstract
Background: We aimed to evaluate the correlation between p16ink4a-overexpression and high risk (hr)HPV-DNA in
vulvar squamous cell carcinoma (vSCC) tumors as well as the impact of both biomarkers on the prognosis of vSCC
patients.
Methods: PCR-detection of (hr)HPV-DNA and immunohistochemical staining for p16ink4a were conducted in 85
vSCC tumors. Survival analyses included the Kaplan–Meier method, log-rank test and Cox proportional hazards
model.
Results: p16ink4a-overexpression and (hr)HPV-DNA were detected in 35 and 37 of the 85 tumors, respectively.
Among the 35 p16ink4a-positive tumors, 10 lacked (hr)HPV-DNA (29 %). Among the 50 p16ink4a-negative tumors, (hr)
HPV-DNA was detected in 12 cases (24 %). The median follow-up was 89.20 months (range 1.7–189.5 months).
P16ink4a-overexpression, but not (hr)HPV-DNA positivity of the primary tumor, was correlated with prolonged overall
survival (OS) (p = 0.009). P16ink4a-overexpression predicted a better response to radiotherapy (p < 0.001). Univariate
analysis has demonstrated that age (p = 0.025), tumor grade (p = 0.001), lymph node metastasis (p < 0.001), FIGO
stage (p < 0.001), p16ink4a-overexpression (p = 0.022), and adjuvant RTX (p < 0.001) were prognostic factors for OS.
Multivariate analysis has demonstrated that lymph node metastasis (HR 1–2.74, 95 % CI 1.50–5.02, p = 0.019), tumor
grade (HR 1–2.80, 95 % CI 1.33–5.90, p = 0.007) and p16ink4a-overexpression (HR 1–2.11, 95 % CI 1.13–3.95, p = 0.001)
are independent prognostic factors.
Conclusion: The discovered overlap suggests the use of p16ink4a in combination with HPV-DNA detection as an ancillary
test for future research and clinical studies in vSCC. The prognostic and predictive value of p16ink4a-overexpression should
be tested in larger cohort studies.
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Background
Vulvar cancer has an incidence of 1–2 per 100,000
women per year and represents 3–5 % of all
gynecological malignancies. The most common type of
vulvar cancer is vulvar squamous cell carcinoma (vSCC)
[1]. Two different etiopathogenic pathways have been
shown to be involved in vSCC development: one is
induced by transforming infections in human papilloma-
virus (HPV) high-risk (hr) genotypes, and the other
arises in the absence of HPV in the setting of long-
standing dermatosis [2]. Histologically, HPV-positive
vSCCs are of the basaloid or warty type and arise from
the vulvar intraepithelial neoplasia (VIN) of the usual
type. In HPV-transformed cells, the downstream
p16ink4a-CDK4-pRB pathway is blocked by the inactiva-
tion of pRB through the HPV E7 protein, and it results
in the nuclear and cellular accumulation of the cyclin-
dependent kinase inhibitor p16ink4a [2, 3]. Although it
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was suggested that p16ink4a-overexpression in vulvar
cancer correlates with the presence of HPV [4], a recent
study revealed substantial mismatch between p16ink4a-
overexpression and HPV status [5].
HPV-dependent and HPV-independent vSCCs were
suggested to be separate entities [2]; however, the prognos-
tic impact of the HPV etiology in vSCC is controversial [6].
The aim of this study was to assess the prevalence of
HPV genotypes and the concordance between the pres-
ence of (hr)HPV-DNA and p16ink4aoverexpression within
vSCC tumors. The secondary aim was to analyze the prog-
nostic significance of p16ink4a and (hr)HPV-DNA status in
vSCC patients.
Methods
This retrospective study was approved by the Polish
Ministry of Science and Higher Education review board
(decision number for approval 2835/B/P01/2009/36).
The board determined that further informed consent
was not required, as all patients provided informed con-
sent for tissue sampling prior to surgical treatment,
including written consent for the storage of their infor-
mation in the hospital database and the use of their
information for research.
Patients and specimens
We studied 85 patients with primary vSCC who under-
went surgical treatment at the Department of Gynaeco-
logical Oncology at The Medical University of Gdańsk
between January 2002 and December 2007. All patients
underwent standard surgical treatment, which was not
modified by the results of the sentinel node procedure.
A wide local excision was performed if the tumor diam-
eter did not exceed 2 cm and the depth of invasion was
less than 1 mm. In cases of lateral tumors with an inva-
sion greater than 1 mm, a wide local excision or tailored
radical vulvectomy with a bilateral inguinofemoral
lymphadenectomy was performed. Lymphadenectomies
were mostly performed with separate incisions. Postop-
erative radiotherapy was administered to all patients
with positive inguinal lymph nodes, with the exception
of those patients who had both a well-differentiated hist-
ology of the primary tumor and also only one lymph
node metastasis. Overall, 33 (39 %) patients received
adjuvant radiotherapy. Clinical data were obtained
from the medical records and questionnaires designed
specifically for our previous studies conducted in the
same cohort [7, 8].
Histopathological data on 76 tumors were obtained
from two previous studies [7, 8]. Nine new tissue speci-
mens were added (collected from consecutive patients
treated in 2007) and newly reviewed with the same
pathological criteria.
Tumor type (pT), depth of invasion (measured from
the epithelial-dermal junction of the adjacent, most
superficial dermal papillae to the deepest point of inva-
sion), tumor grade according to the GOG (Gynecological
Oncology Group) and lymph nodes status (pN) were
verified by the same two independent pathologists
(without knowledge of the disease outcome). All of
these patients were staged according to the new 2009
FIGO system for vulvar cancer [9].
Finally, immunohistochemical (IHC) staining for
p16ink4a and PCR detection of HPV-DNA were per-
formed on 85 paraffin-embedded tissue samples from
the primary tumors.
Antibodies
Mouse anti-human p16ink4a monoclonal (sc-56330) anti-
body was obtained from Santa Cruz Biotechnology (USA).
Immunohistochemistry
For immunohistochemical staining, four-micron-thick
serial sections were cut, placed onto slides, and deparaf-
finized. For epitope retrieval, slides were immersed in
Target Retrieval Solution (pH 6.0; Dako Cytomation,
Denmark) and heated in a pressure cooker. The slides
were incubated for 90 min with primary antibodies. The
reaction was visualized using the Novolink Polymer De-
tection System (Novocastra Laboratories). Appropriate
positive and negative controls were included for each
case. As a positive control, a case of HPV-related cer-
vical cancer was used. For the negative control, the pri-
mary antibody was replaced with normal mouse IgG at
an appropriate dilution. Immunohistochemistry results
were evaluated by two independent pathologists, who
were blind to the clinical data. The concordance rate
between their observations was over 96 %.
Evaluation and classification of p16ink4a immunostaining
The evaluation of the p16ink4a immunostaining was per-
formed on 3 different staining patterns: negative, focal,
and diffuse staining. For statistical purposes, p16 immu-
nostaining was classified as positive or negative. Staining
for p16ink4a was considered positive only in cases with a
strong diffuse and continuous nuclear/cytoplasmic ex-
pression of p16ink4a within the cancer nests (focal and
weak diffuse staining were considered negative).
Detection of DNA HPV
Tissue dissection and DNA preparation
Genomic DNA was prepared from two to three 4 mm
sections from each case using standard methods. DNA
was obtained from the samples by incubating them with
250 μl proteinase K solution (1 mg/ml) for 16 h at 70 °C.
Following heat inactivation at 95 °C for 10 min, 10 μl of
the supernatant was used for PCR. Appropriate positive
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and negative controls were incorporated during the DNA
preparation and subsequent testing to monitor test
performance.
Specimen extracts were also tested by real-time PCR
for the human RNase P gene to monitor specimen
quality.
Mucosal HPV DNA amplification and genotyping
Broad-spectrum HPV DNA amplification and mucosal
HPV genotyping was performed using the SPF10–
LiPA25 system (SPF10 HPV LiPA, version 1; manufac-
tured by Labo Biomedical Products, Rijswijk, The
Netherlands), as described previously [10, 11]. All testing
was commercially done in the DDL Diagnostic Labora-
tory in Rijswijk, The Netherlands, according to the
instructions of the manufacturer. First, SPF10 PCR was
used to amplify a 65-base pair fragment from the L1 re-
gion of the HPV genome. The amplimers from all sam-
ples were subsequently tested with the DNA Enzyme
Immuno-Assay (DEIA). This method provides an optical
density value and is able to detect the SPF10 amplimer
from more than 68 HPV types. Amplimers from positive
samples can be used to identify 25 individual HPV geno-
types (high-risk HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 70, and low-risk HPV: 6, 11, 34, 40,
42–44, 53, 54, 74) simultaneously in a reverse
hybridization assay (RHA) by hybridization to DNA
probes attached to nitrocellulose strips. After the RHA,
the strips were dried, and the purple colored bands were
visually scored and interpreted by aligning them with
the standard grid.
No aberrant results were observed in the sectioning,
DNA isolation or PCR controls.
Follow up analysis
The impact of the following variables on overall survival
was assessed: type of the tumor (pT), lymph node status
(pN), tumor grade, depth of invasion, FIGO stage, age
and recurrence, as well as p16ink4a and HPV-status.
Statistical analysis
To determine statistically significant differences between
the variables, the Mann-Whitney U test was used. Over-
all survival (OS) curves were estimated using the
Kaplan-Meier method and compared using a two-sided
log-rank test. Independent variables were first analyzed
with univariate analysis. Variables shown by univariate
analysis to be significantly associated with survival were
entered into a Cox proportional hazards regression
model for multivariate analysis. A p value <0.05 was
considered significant. All analyses were performed
using Statistica 10 software (Stat Soft Inc. USA).
Results
Study population
The clinicopathological features of the patients with pri-
mary vSCC and their relationships to the course of the
disease are summarized in Additional file 1: Table S1
and Additional file 2: Table S2, respectively. The median
age of the patients was 68 years (range 36–85 years),
and the median duration of the overall follow-up was
89.20 months (range 1.7–189.5 months). The 5-year dis-
ease free survival (DFS) rate was 61.75 %. Recurrence
was observed in 16 patients (16/85, 18.82 %); 13 had
local recurrence (13/85, 15.29 %) and three revealed re-
currence in the groin (3/85, 3.53 %).
The depth of invasion in pN-positive (median 8.2 mm)
and pN-negative cases (median 6.0 mm) was signifi-
cantly different (U–MW test, p = 0.000743).
Immunohistochemical expression of p16ink4a
Staining for p16 was performed within the nuclei and
the cytoplasm of the cancer cells (Fig. 1a). The 85 pa-
tients were divided into 2 groups based on p16 status:
p16ink4a-negative (n = 50) (Fig 1b, c) and p16ink4a-positive
(n = 35) (Fig. 1a).
Detection of (hr)HPV-DNA
HPV-DNA was detected in 38 of the 85 primary vSCC
tumors (45 %).
The HPV genotype distribution is provided in Additional
file 3: Table S3. HPV16 was the most prevalent type de-
tected (33/38 cases, 86.8 % of infected tumors). HPV33
was found in 2 tumors, HPV56 in one tumor, and the sim-
ultaneous occurrence of 16 and 18, and 39 and 59 HPV
types was identified in one tumor each. The low risk HPV6
genotype was detected in one tumor, and this case was
indexed as (hr)HPV-DNA-negative. Finally, 85 patients
were divided into 2 groups based on (hr)HPV-DNA status:
negative (n = 48) and positive (n = 37).
Overlap between p16ink4a-overexpression and (hr)HPV
status
Among the 35 vSCC tissue samples with p16ink4a-over-
expression, 10 cases lacked (hr)HPV-DNA (28.6 %).
Among the 50 tumors without p16-overexpression,
(hr)HPV-DNA was detected in 12 cases (24.0 %). The
combined presence of (hr)HPV-DNA and p16-
overexpression was detected in 25 of the 85 cases
(29.4 %). P16ink4a status in 85 vSCC cases in relation to
(HR)HPV genotypes is summarized in Table 1.
Prognostic significance of p16ink4a
The OS (months) of patients with p16ink4a-positive and
p16ink4a-negative vSCC was 98.97 and 23.33, respectively
(p = 0.009). A positivity for p16ink4a in the primary
tumor correlated with a prolonged survival of vSCC
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patients (p = 0.010) (Fig. 2a). There was no significant
difference in the proportion of p16ink4a-positive and
p16ink4a-negative patients who received adjuvant radio-
therapy (12/35 [34 %] vs. 21/50 [42 %]; p = 0.506). The
median OS (months) of radiated patients with p16ink4a-
positive and p16ink4a-negative vSCC was 36.93 and 7.47,
respectively. A positivity for p16ink4a predicted longer
OS among vSCC patients who received adjuvant radio-
therapy (p = 0.0006) (Fig. 2b).
Prognostic significance of (hr)HPV-DNA
The median OS (months) of patients with (hr)HPV-
DNA-positive and (hr)HPV-DNA-negative vSCC was
69.31 and 41.02, respectively (p = 0.41). A positivity for
DNA of (hr) HPV in the primary tumor was not corre-
lated with a prolonged survival of vSCC patients (p =
0.411) (Fig. 2c). There was no difference in the propor-
tion of (hr)HPV-DNA-positive and (hr)HPV-DNA-nega-
tive patients who received adjuvant radiotherapy (15/37
[41 %] vs. 18/48 [37 %]; p = 0.825). The OS (in months)
of radiated vSCC patients with tumors positive and
negative for (hr)HPV-DNA was 18.92 and 15.77, respect-
ively. A positivity for (hr)HPV-DNA did not predict lon-
ger OS among vSCC patients who received adjuvant
radiotherapy (p = 0.201) (Fig. 2d).
Prognostic value of other clinicopathological variables
Recurrence
Recurrence was correlated with decreased overall sur-
vival (p = 0.0411) (Fig. 3a).
pT and pN status (according to the TNM system)
Most of the cases were staged as T1 (76/85, 89.41 %).
Tumor type (pT: T1 (n = 76), T2 (n = 8), T3 (n = 1), T4
(n = 0)) has not revealed any influence on overall sur-
vival (p = 0.5027).
Nodal status (pN: N0 vs. N1/N2) has a significant im-
pact on overall survival (p = 0.00006) (Fig. 3b).
Histological tumor grade
We found significant differences in the overall survival
between patients with different histological tumor grades
(divided in accordance with the three-tier grading
scheme: G1/G2/G3) (p = 0.00055) (Fig. 3c), as well as
between cases with well-differentiated (differentiation
grade 1) and poorly-differentiated tumors (differenti-
ation grades II–III) (p = 0.00021).
Depth of invasion
We did not manage to find any borderline depth of inva-
sion with a significant impact on overall survival (for
7 mm (median) p = 0.057).
Adjuvant radiotherapy
Thirty-three patients who received adjuvant radiotherapy
had a significantly worse prognosis compared to patients
(n = 52) without irradiation (p = 0.00001) (Fig. 3d).
FIGO stage
The stage distribution according to the 2009 FIGO sta-
ging system was as follows: stage I: 44 (51.76 %), stage
II: 2 (2.35 %), stage III: 35 (41,18 %) and stage IV 4
(4,71 %). The cumulative 5-year survival was as follows:
stage I: 67 %, stage II: no data (too small of a group- 2
cases), stage III: 27 % and stage IV: 25 % (p = 0.00379)
(Fig. 3e).
Age
Patients older than 60 years had a significantly worse
prognosis (p = 0.004) (Fig. 3f ).
Fig. 1 Microphotographs of immunohistochemical staining for p16ink4a: a. strong diffuse nuclear/cytoplasmic expression - p16ink4a positive cases;
b. p p16ink4a negative cases; c. focal check-board pattern of expression - p16ink4a -negative cases
Table 1 (HR)HPV genotype distribution and p16 status in 85
vSCC cases. (All samples were sufficient for HPV DNA testing)
(HR)HPV-DNA Total number P16-positive P16-negative
negative 48 10 38
positive 37 25 12
type16 31 21 10
type 16 and 18 1 0 1
type 33 3 2 1
type 56 1 1 0
type 39 and 52 1 1 0
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Univariate and multivariate analyses of prognostic
variables in vSCC patients
In the univariate analysis, age (p = 0.0254), lymph node
status (p = 0.0005), tumor grade (G1 vs. G2 + G3) (p =
0.001), adjuvant radiotherapy (p = 0.000005) and p16-
overexpression (p = 0.0216) were prognostic factors for
OS (Table 2). Multivariate analysis revealed that p16-
expression (hazard ratio [HR] = 2.11, 95 % confidence
interval [CI] = 1.13–3.95, p = 0.001), nodal status (HR =
2.74, 95 % CI = 1.50–5.02, p = 0.019), and tumor grade
(HR = 2.80, 95 % CI = 1.33–5.90, p = 0.007) were inde-
pendent prognostic factors for OS (Table 3).
Discussion
The prevalence of HPV-positive tumors in our series
was nearly 44.7 %. Previous studies on vSCC have re-
ported highly variable numbers of HPV-positive cases
that have ranged between 0 and 66 % depending on the
method of HPV detection and the histological types of
vSCC analyzed [12–15].
In 2013, de Sanjosé S et al. reported 28.6 % HPV-
positive cases among 1709 invasive vulvar cancers (IVC)
[5]. An overestimation of HPV positivity in our cohort
could be generally explained by different case selection, as
both studies were conducted in the same Laboratory
(DDL Diagnostic Laboratory in Rijswijk, The Netherlands)
with an identical protocol using SPF-10 broad-spectrum
primers and genotyping with a reverse hybridization line
probe assay (LiPA25).
Indeed, all of our cases come from Poland (Europe)
while only 49.8 % of women with IVC included in de
Sanjosé’s study were European. The prevalence of
HPV-DNA was found to be higher among European
women than women living in other geographical re-
gions [5].
Additionally, the number of well differentiated tumors
was higher in our group than in IVC cohort described
by Sanjosé S et al. (76 % vs. 71 %).
Indeed, the proportion of histological types is crucial
for cohort prevalence, as it was shown that HPV-
positivity among warty-basaloid and keratinizing vSCC
Fig. 2 Prognostic significance of p16ink4a-overexpression: a. general patient cohort; b. patients requiring adjuvant radiotherapy; (hr)HPV-DNA: c. general
patient cohort; d. patients requiring adjuvant radiotherapy
Sznurkowski et al. BMC Cancer  (2016) 16:465 Page 5 of 9
tumors varies, and it was described as 69 and 11.5 % of
cases, respectively [5].
Our study confirmed the predominant contribution of
HPV-16 to the etiology of HPV-related vulvar cancer
and suggested that other HPV types, such as HPV-33,
HPV-18 and HPV-56, which are common in cervical
cancer, are also important to vulvar carcinogenesis,
although to a lesser degree.
In 28.6 % of p16ink4a-positive tumors, a lack of
(hr)HPV-DNA was observed, and in 24.0 % of p16ink4a-
negative tumors, (hr)HPV-DNA was detected. The
substantial mismatch between p16ink4a-overexpression
and HPV-status reported here was also observed in the
largest cohort of 1709 vSCC cases [5]. Seventeen percent
of tumors expressing p16ink4a lack (hr)HPV-DNA, and
9.4 % of tumors lack p16ink4a-overexpression despite the
presence of (hr)HPV-DNA [5].
A lack of (hr)HPV-DNA in p16-positive tumors could
be explained by the fact that the HPV oncoprotein, E7,
which functionally inactivates RB, is not the only thing
responsible for the increases in p16ink4a expression [16].
Although it is believed that RB inactivation is a requisite
for the elevation of p16ink4a expression in cancer [2, 3],
aberrations in the RB pathway are not obvious in every
tumor. The RB checkpoint is deregulated by multiple
mechanisms independent of RB1 mutation, deletion or
methylation. The viral oncogene expression represents
just one potential form of multiple possible ways of RB
inactivation [16].
Fig. 3 Prognostic significance of clinicopathological variables: a. recurrence: no reccurence/recurrence; b. pN: pN0/pN1/pN2; c. Tumor
grade: G1/G2/G3; d. Adjuvant radiotherapy: RTX-/RTX+; e. FIGO stage: I/II/III/IV; f. Age: > = 60/<60 years
Table 2 Univariate analyses of survival in vulvar cancer patients
Variables Categories Overall survival p
HR 95 % CI
Nodal status Negative for metastases 1 1.59–5.22 0.0005
Positive for metastases 2.88
Adjuvant RTX Yes 1 2.22–7.30 0.000005
No 4.02
Histologic grade Low (G1) 1 1.65–7.15 0.001
High (G2 + G3) 3.43
p16 status Positive 1 1.11–3.81 0.0216
Negative 2.06
FIGO stage I, II, III, IV 1.62 1.23–2.12 0.000592
Depth of invasion Continuous 1.05 0.96–1.15 0.283261
Age <60 1 1.12–5.59 0.025436
>60 2.5
Table 3 Multivariate analyses of survival in vulvar cancer patients
Variables Categories Overall survival p
HR 95 % CI
Nodal status Negative for metastases 1 1.50–5.02 0.019
Positive for metastases 2.74
Histologic Grade Low (G1) 1 1.33–5.90 0.007
High (G2 + G3) 2.80
p16 status Positive 1 1.13–3.95 0.001
Negative 2.11
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Several findings have proven the strong association be-
tween age-promoting, ‘gerontogenic’ signals and p16ink4
expression [16]. Thus, the impact of senescence and
inflammation on p16ink4 expression in our older age
cohort of vSCC patients should also be considered.
There remains the possibility that a certain fraction of
HPV-negative samples were false negatives. However,
during the testing, we checked all the samples for ampli-
fiable human genomic DNA. All samples showed the
presence of human DNA by PCR (RNAseP gene). The
size of the PCR fragment in this test is also 65 base
pairs, and therefore, it is most sensitive PCR for
formalin-fixed paraffin-embedded/FFPE/tissue samples.
(hr)HPV-DNA-positive cancer cases without marked
p16-overexpression could be explained by the fact that
close to half of all human cancers show p16Ink4a-inacti-
vation, ranging from 25 to 70 % [17]. Such an event
could exist parallel to functional inactivation of RB by
the E7 protein. Some of the HPV-positive samples could
also be false positive. By performing Laser Capture Mi-
crodissection [18], it is possible to assign HPV types to
the lesional cells themselves; however, it was not per-
formed in the current study. Therefore, we cannot ex-
clude the possibility of contamination of the cancer
samples by HPV virions from the surrounding vulvar
epithelium.
Taking these facts together, we postulate not to treat
p16ink4a-overexpression as a surrogate marker for
(hr)HPV infection in vSCC. The correlation between
p16ink4a and (hr)HPV-DNA varies in squamous cell
carcinomas. In cervical cancer, p16ink4a overexpression
and (hr)HPV status are quite well correlated [19],
while in oral cancer, a lack of concordance is fre-
quently reported [20].
The combined presence of (hr)HPV-DNA and
p16ink4a-overexpression was detected in 25 of the 85
cases (29.4 %). This result is in the range of the series re-
ported by de Sanjosé S et al., who have reported 22.4 %
HPV-driven cases out of 1709 vSCCs [5]. Probably, this
is the real contribution of the HPV infection to vSCC
development.
In the following analyses, we assessed the prognostic
significance of (hr)HPV-DNA status and p16 overex-
pression separately. The (hr)HPV-DNA status of the
primary tumor has no impact on the survival of
vSCC patients. P16-overexpression was found to be
prognostic, and also predicted a better response to
radiochemotherapy.
Several reports investigating the relationship between
HPV DNA and vSCC prognosis have produced conflict-
ing results [6, 21–24]. Two old studies from the early
1990s [23, 24] reported a better survival in DNA HPV-
positive patients, but their results are both hampered by
the limited number of cases included (55 and 60,
respectively) and the tests used for HPV detection. In re-
cent years, one paper (with a median follow up of
42 months) confirmed a prolonged survival in patients
with vSCC tumors positive for high risk DNA HPV [22],
but two others (with a longer follow up) denied the
prognostic significance of HPV DNA within cancer
tissue [6, 21].
We identified only two studies that utilized p16 ex-
pression for the survival analysis of vSCC patients, and
they reported contradictory results [6, 25]. Our results
were consistent with the findings of Tringler et al. [25],
but they were in opposition to the results of Alonso et
al. [6], who did not identify p16 status as a prognostic
indicator of vSCC. The low prevalence of p16-positive
tumors (19 % [19/98]) might explain the lack of prog-
nostic significance of p16 status in the Alonso et al.
study, whereas the percentage of p16-positive cases in
our study and that by Tringler et al. [25] was 41 % (35/
85) and 43 % (34/80), respectively. The median follow-
up in the Alonso et al. cohort was only 45 months [6],
while it was 52 and 89 months in the Tringler study [25]
and our study, respectively.
The conducted univariate and multivariate analyses
revealed that p16-overexpression is an independent
prognostic factor with respect to survival.
RB inactivation releases p16Ink4a from its negative
feedback control, causing a paradoxical increase in the
levels of this protein, which attempts to inhibit uncon-
trolled cellular replication [26]. Thus, it is not surprising
that p16ink4a-overexpression itself (not the HPV virus)
has a protective role in HPV-related malignancies.
It was shown that cancers that present p16Ink4a-over-
expression are very sensitive to radiotherapy, and they
have a better prognosis [27]. A better response to radio-
chemotherapy has been associated with a more favorable
prognosis of HPV-positive head and neck cancers
[28–32]. Indeed, we also confirmed that p16Ink4a-over-
expression predicts a better clinical outcome among
patients requiring adjuvant radiotherapy. The two
compared groups (irradiated p16-positive and p16-
negative) were similar in terms of the number of positive
nodes and the presence of extracapsular spread, which
strongly supports this conclusion.
This study has the traditional weaknesses of a retro-
spective design, and the results obviously represent a
small cohort. Lack of information on smoking and cause
of death potentially limit the prognostic analysis. The
strengths of the study include the treatment of patients
according to uniform standards and a sufficient follow-
up duration to reveal recurrences and to allow for the
reliable assessment of the prognostic significance of all
analyzed biomarkers. Data on (hr)HPV-DNA prevalence
were provided by highly experienced sources in the
HPV-DNA detection laboratory.
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Conclusions
The overexpression of p16ink4a is not a surrogate marker
for a transforming infection with HPV high-risk geno-
types in vSCC. This suggests the use of p16ink4a in com-
bination with HPV DNA-detection as an ancillary test
for research and clinical studies when HPV is not a ne-
cessary cause. The prognostic and predictive significance
of p16Ink4a-overexpression within cancer tissue requires
further investigation in future prospective studies.
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